Navigation Links
Pharmasset to Present at Canaccord Adams Conference
Date:8/5/2009

tment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates: RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys((R)) and Copegus((R) )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
4. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
5. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
8. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
9. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
10. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
11. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 EvoDerma ’s NOOME Anti-Aging Motion ... device now comes with a second treatment cup to help ... The new cup is thinner on the edges for a ... rough, thin and uneven surfaces on the face, neck and ... stimulating treatment on areas such as the cheeks and neck, ...
(Date:7/10/2014)... DALLAS , July 10, 2014  Kainos Capital, ... consumer brands, today announced that it has acquired the ... stake in the business. Terms of the transaction were ... loss and meal replacement business that markets ready-to-drink shakes, ... North America and in the ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
(Date:7/10/2014)... disorders has been extremely challenging because there are many ... to cause disease. Now investigators reporting in the July ... Stem Cell describe a strategy that may help ... risk factors or environmental exposures to affect the development ... variant that may predispose individuals to schizophrenia. , ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2
... the nation,s top-10 GPOs(1), IRVINE, Calif., ... CO-Oximetry and Read-Through Motion and Low Perfusion ... three-year supplier agreement,with HealthTrust Purchasing Group (HealthTrust), ... hospitals, ambulatory surgery,centers, alternate care sites and ...
... /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation (OTC ... portions of the recently completed and announced ... for 2008,and employee recognition ceremonies., Highlights ... Zhang, Director and General Manager of Kiwa ...
... Two Development Milestones in its Ofatumumab ... Collaboration With GlaxoSmithKline., COPENHAGEN, January 21 ... second and third development milestones,for ofatumumab (HuMax-CD20(R)) under the terms ... of the collaboration of DKK 87.2 million,was triggered by treatment ...
Cached Biology Technology:Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 2Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 3Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 4Kiwa Posts Video of 2007 Annual Management Meetings 2Kiwa Posts Video of 2007 Annual Management Meetings 3Genmab Reaches Milestones in Ofatumumab Collaboration 2Genmab Reaches Milestones in Ofatumumab Collaboration 3
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
(Date:7/10/2014)... cities in New Mexico, nearly every public golf course ... precious potable water supplies. Across the U.S. Southwest as ... receive treated effluent. Reusing the effluent increases the sustainability ... homeowners alike fertilize their lawns during the growing season. ... Mexico State University turfgrass expert has a new vision ...
(Date:7/10/2014)... Smart technology emphasis grows in biometrics ... security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... Inc. (NASDAQ: AAPL ), Visa Inc. (NYSE: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the ... series of 30 second spots on CNBC for its next ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... skin like a temporary tattoo, can alert marathoners, competitive bikers ... "hit the wall," scientists are reporting. The study, in ACS, ... of the sensor, which also could help soldiers and others ... monitor stamina and fitness. Joseph Wang and colleagues ...
... those painful lip blisters known as cold sores has an internal ... to literally blast its infectious DNA into human cells, scientists are ... the first in a human virus opens the door ... in the Journal of the American Chemical Society . ...
... MINNEAPOLIS/ST. PAUL (July 23, 2013) Mere months after ... the United States swine population, University of Minnesota researchers ... The first-of-its-kind test, which is available now, provides a ... U.S. PEDV strains. Characterized by acute diarrhea ...
Cached Biology News:U of M researchers unveil nation's first porcine virus rapid detection test 2
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
IkappaB-alpha (112B2) Mouse mAb...
...
Biology Products: